Translational research : the journal of laboratory and clinical medicineJul 21, 2026

How SGLT2 inhibitors and GLP-1 receptor agonists work together in treating chronic kidney disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 23, 2026

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RAs) may have distinct yet complementary effects on kidney and cardiovascular health in chronic kidney disease.

SGLT2 inhibitors may reduce kidney disease progression and heart failure risk by promoting kidney function and altering metabolic processes.
GLP-1 receptor agonists may provide cardiovascular benefits by reducing inflammation and supporting blood vessel health.
Both treatments may enhance mitochondrial function and cellular maintenance, contributing to overall kidney and cardiovascular protection.
The relationship between SGLT2i and GLP-1RA benefits in chronic kidney disease is not fully understood and requires further investigation.
A phenotype-aware approach could help in addressing residual risks and guiding future research on combination therapies.

Simplified

Chronic kidney disease is a central node of the cardio-kidney-metabolic continuum and carries substantial residual cardiovascular and kidney risk. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have reproducibly reduced kidney disease progression and heart failure risk in CKD outcomes trials, whereas GLP-1RAs have established cardiovascular benefit across cardiometabolic populations. The FLOW trial (Evaluate Renal Function With Semaglutide Once Weekly) established hard kidney-outcome evidence for semaglutide in type 2 diabetes with CKD, although whether this renal benefit represents a broader GLP-1RA class effect remains unresolved. This review synthesizes current evidence through a translational framework centered on mechanistic complementarity rather than simple add-on therapy. SGLT2 inhibitors predominantly provide proximal tubular and hemodynamic offloading, coupled with fasting-mimetic metabolic reprogramming that may improve oxygen-stress balance and cellular housekeeping. GLP-1RAs predominantly support an immune-vascular repair program by dampening sterile inflammation, preserving endothelial integrity, and limiting fibrotic amplification. These pathways appear to converge at mitochondrial homeostasis, autophagy, and barrier stability. We argue that the most useful clinical implication at present is not a fixed prescribing algorithm, but a phenotype-aware way to frame residual risk, sequence future studies, and define mechanistic endpoints for combination strategies across chronic kidney disease phenotypes.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 8

authors report competing interests

8 report none

PubMed

How SGLT2 inhibitors and GLP-1 receptor agonists work together in treating chronic kidney disease

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief